biomodal and Element Biosciences Unite for Enhanced Multiomic Insights
Why is the integration of multiomic solutions critical in the life sciences industry? biomodal, an omics-based life sciences technology and analytics company, has announced at the AGBT 2026 General Meeting that its duet multiomic solutions are now compatible with Element Biosciences’ AVITI24™ 5D multiomics and AVITI™ sequencing instruments. This collaboration, validated at the University of Minnesota (UMN) Genomics Center, aims to enhance sensitivity and accelerate clinical research in areas such as cancer, aging, and neurodegenerative diseases.
“By combining biomodal’s duet multiomic solutions with the Element AVITI system, our clients gain insights into disease processes that are not accessible without a 6-base genome,” said Dr. Kenny Beckman, Director of the UMN Genomics Center. “We’re excited to extend this capability to our researchers as they work to uncover a deeper mechanistic understanding of disease.”
Key Insights at a Glance
- Enhanced Sensitivity: The integration delivers enhanced sensitivity for applications including cancer, aging, and neurodegenerative disease.
- Sequencer Agnostic Solutions: biomodal’s technology is designed to be platform agnostic, ensuring researchers have access to the highest quality multiomic data.
- Seamless Workflow: AVITI and AVITI24 users gain access to biomodal’s software pipeline, expanding the analytical power of their sequencing workflows.
- Future Compatibility: biomodal will explore compatibility with future Element systems.
Why Multiomic Integration Is Crucial for Clinical Research
The integration of multiomic solutions is essential for advancing clinical research. By combining genetic and epigenetic data, researchers can gain a more comprehensive understanding of complex diseases. This is particularly important in fields such as cancer, aging, and neurodegenerative diseases, where a single type of data often falls short in providing a complete picture. The collaboration between biomodal and Element Biosciences addresses this gap, offering a streamlined, end-to-end workflow that enhances the accuracy and efficiency of next-generation sequencing (NGS) data analysis. This integration is crucial for accelerating the pace of research and driving precision medicine forward.
Why the Window for Action Is Closing Fast
Just as a race car driver must optimize every aspect of their vehicle to win, researchers must leverage the most advanced tools to make breakthroughs in life sciences. The partnership between biomodal and Element Biosciences is a significant step in this direction. By providing enhanced multiomic insights, the integration helps researchers uncover disease mechanisms that were previously inaccessible. This is particularly urgent as the demand for precision medicine grows, and the need for accurate, actionable data becomes more pressing. The next steps involve expanding the use of these integrated solutions to a broader range of research applications.
biomodal Mobilizes for Multiomic Research Advancements
biomodal is committed to building technologies and analytics that enable life scientists and clinical developers to capture the 6-base genome and provide insight into the complexity and dynamism of biological systems. The company’s duet multiomics solutions, which are sequencer agnostic, integrate a pre-sequencing workflow with post-sequencing informatics to generate highly accurate genetic and epigenetic data from a single sample in a single run. Through this partnership with Element Biosciences, biomodal is delivering the novel benefits of its duet multiomic solutions to better support life sciences customers worldwide. Peter Fromen, CEO of biomodal, emphasized, “We designed our technology to be platform agnostic to ensure researchers have access to the highest quality multiomic data.”
Future Outlook
The integration of biomodal’s duet multiomic solutions with Element Biosciences’ sequencing instruments is like a bridge connecting two powerful research tools. This bridge not only enhances the capabilities of each system but also accelerates the pace of discovery. As the collaboration continues to evolve, the potential for uncovering new insights into complex diseases grows. biomodal will explore compatibility with future Element systems, ensuring that researchers have access to the most advanced multiomic solutions.
Conclusion
The partnership between biomodal and Element Biosciences marks a significant advancement in multiomic research. By providing enhanced sensitivity and a seamless workflow, this integration accelerates the pace of clinical research and drives precision medicine forward. Join the conversation in the comments below.
About the technology
biomodal is focused on building technologies and analytics as research tools for life scientists and clinical developers, enabling them to capture the 6-base genome and provide insight into the complexity and dynamism of biological systems in health and disease. The company’s solutions, which are sequencer agnostic, work with existing infrastructure, integrating a pre-sequencing workflow with post-sequencing informatics to generate highly accurate genetic and epigenetic data from a single sample in a single run.
Source link: https://www.businesswire.com/
